Inside RFK Jr.’s financials

Documents STAT obtained through a public records request show interests Kennedy might need to forgo as HHS secretary.

January 10, 2025 Check out STAT+

Sponsored By

ALLISON ROBBERT/AFP via Getty Images STAT+ | Inside RFK Jr.'s financials: Biotech investment, health care consulting, 'author introductions'  Documents show Robert F. Kennedy Jr. invested in biotechs and consulted on health care — interests he might have to forgo as health secretary. By Isabella Cueto STAT+ | Biden's top antitrust official calls for breaking up powerful health care companies Giant health care companies use their power to extract excessive profits and create an unequal playing field for smaller rivals, Biden's top antitrust official said By Bob Herman Patrizia Cavazzoni, head of FDA's drug center, to leave the agency Public health experts have expressed concern that longtime FDA staff may leave due to fears of working in an antagonistic environment By Lizzy Lawrence and Adam Feuerstein Adobe In debate over obesity medications, FDA shifts toward importance of drugs in subtle ways In new guidance, the agency mentions lifestyle interventions less than previously and takes a less conservative view of how drugs should be tested in kids. By Elaine Chen STAT+ | Spurred by AI's possibilities, Eli Lilly and Andreessen Horowitz partner on $500M venture fund The drugmaker and the venture capital firm will look at new technologies in the "biotech ecosystem," with a focus on artificial intelligence. By Matthew Herper Opinion: Continuing surveillance of emerging disease threats is vital for public health, national security Former FDA chiefs warn against Trump administration emphasis on chronic disease, call CDC emerging infectious disease monitoring a national security issue. By Scott Gottlieb and Mark B. McClellan Adobe STAT+ | Trio behind MyoKardia raise $300 million for new biotech firm focused on heart disease Funding for the company, which will focus on targeted drugs for heart disease, comes from Perceptive Advisors, ARCH Venture Partners, and Sequoia Heritage. By Matthew Herper

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser